Cluster 2, characterized by hypomethylation of genes like RORC, S100A13, and TNF, correlates with higher tumor mutation burden (TMB) and better immunotherapy responses, as higher TMB generates neoantigens that activate immune responses [71]. The gene discussed is TNF; the disease is neoplasm.